Novavax coronavirus vaccine induces immune response in small study

FILE PHOTO: A woman holds a small bottle labeled with a "Vaccine COVID-19" sticker and a medical syringe in this illustration taken April 10, 2020. REUTERS/Dado Ruvic/File Photo

(Reuters) - Novavax Inc said on Tuesday its experimental COVID-19 vaccine produced antibodies against the novel coronavirus, according to initial data from a small, early-stage clinical trial.

The company said it would likely move forward with the lower of two tested doses of the vaccine. It reported that eight study participants experienced adverse side effects after receiving a second vaccine dose during the trial. The company said none required medical intervention.